Q linea

Q linea Current Assets

The Current Assets of Q linea (QLINEA.ST) as of Nov 3, 2026 is 329.85 M SEK. In the previous year, Current Assets was 64.81 M SEK — a change of 408.94% (higher).

Current Assets

329.85 MSEK

YoY

408.94%

Last updated:

Current Assets of Q linea is 2025 329.85 M SEK. Current Assets of Q linea was 2024 64.81 M SEK. It decreases by 408.94% higher compared to the previous year.

The Q linea Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
533.61 M SEK
Jan 1, 2019
250.14 M SEK
Jan 1, 2020
392.72 M SEK
Jan 1, 2021
246.60 M SEK
Jan 1, 2022
160.70 M SEK
Jan 1, 2023
170.66 M SEK
Jan 1, 2024
64.81 M SEK
Jan 1, 2025
329.85 M SEK
The Q linea Current Assets history
YEARCurrent AssetsYoY
329.85 MSEK+408.94%
64.81 MSEK-62.02%
170.66 MSEK+6.20%
160.70 MSEK-34.84%
246.60 MSEK-37.21%
392.72 MSEK+57.00%
250.14 MSEK-53.12%
533.61 MSEK+3,427.76%
15.13 MSEK+5.71%
14.31 MSEK+71.69%
8.33 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Q linea Stock analysis

What does Q linea do? Q-linea AB develops and manufactures in-vitro diagnostic solutions for infectious diseases, focusing on antibiotic susceptibility testing. The company's core product, ASTar, is a fully-automated instrument that provides susceptibility profiles within three to six hours directly from positive blood cultures. This enables early targeted antibiotic administration for sepsis identification in hospital patients, primarily serving hospital laboratories. The firm measures bacteria's antimicrobial susceptibility using its own disposables, which are integral to the ASTar system's operation. Q-linea AB's revenue model is based on selling the ASTar instrument and its associated disposables to hospital laboratories. The company's product is specifically designed for sepsis identification in hospital settings, where rapid and accurate antibiotic susceptibility testing is critical. By providing a faster solution than traditional methods, Q-linea targets hospital labs seeking to improve patient outcomes in sepsis cases. The company operates as a holding company with a focus on developing and manufacturing IVD solutions. Its primary customers are hospital laboratories, which purchase the ASTar system and disposables to streamline their diagnostic processes. The firm's business model centers on the sale of both the instrument and the consumable disposables, creating recurring revenue streams from ongoing disposables usage. Q linea is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Q linea stock

Current Assets of Q linea is 329.85 M SEK in 2025.

Current Assets of Q linea changed from 64.81 M SEK to 329.85 M SEK, representing a 408.94% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Q linea since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Q linea historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Q linea

All Key Metrics — Q linea